Nathan Katz
Class of 2027F, Florida
About
Projects
- "What can doctors do during the 3-4 week bridging period of CAR-T therapy to optimize patients for treatment, and how can they lower the risk of tumor progression while best prepping the body for the therapy? " with mentor Mathias (Working project)
Project Portfolio
What can doctors do during the 3-4 week bridging period of CAR-T therapy to optimize patients for treatment, and how can they lower the risk of tumor progression while best prepping the body for the therapy?
Started July 2, 2026
Abstract or project description
Study: Jacobson et al., 2023. Real-world outcomes with CAR T-cell therapies in large B-cell lymphoma: a systematic review and meta-analysis. Transplantation and Cellular Therapy.
Study Design: A massive systematic review and meta-analysis pooling data from 76 real-world patient cohorts to see how CAR-T therapies perform in everyday clinics outside of perfect clinical trials. The Comparison: It evaluated the real-world performance, survival rates, and toxicities of the two main approved CAR-T products: Axi-cel vs. Tisa-cel. Efficacy vs. Safety Trade-off: Axi-cel demonstrated statistically superior survival and response rates, but carried a massive, nearly 4-fold higher risk of severe neurotoxicity (ICANS) compared to Tisa-cel. The Manufacturing Timeline: Crucially, the analysis noted that Axi-cel had a significantly shorter median time from cell harvesting (apheresis) to final CAR-T infusion than Tisa-cell